Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2024)

Boehringer Ingelheim Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2024)

Docket	1:24-cv-00082	Date Filed	2024-08-29
Court	District Court, N.D. West Virginia	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	None	Referred To
Patents	11,911,388
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-08-29				External link to document

Boehringer Ingelheim v. Mylan, 1:24-cv-00082: Ofev Patent Litigation Analysis

Last updated: August 3, 2026

Boehringer Ingelheim sued Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware after receiving a Paragraph IV certification concerning Mylan’s proposed generic nintedanib product. The case concerns Ofev, Boehringer’s nintedanib capsule product for idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases with a progressive phenotype, and systemic sclerosis-associated interstitial lung disease. The dispute is an ANDA patent case, not a biologic or biosimilar proceeding.

The principal commercial issue is whether Mylan can launch generic nintedanib before the expiration of the Orange Book patents asserted by Boehringer. FDA approval of Mylan’s ANDA would not itself authorize commercial launch while the Hatch-Waxman litigation stay remains in effect or while enforceable patent claims block marketing.

What is Boehringer Ingelheim v. Mylan, 1:24-cv-00082?

Boehringer Ingelheim Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 1:24-cv-00082, was filed in the District of Delaware on January 24, 2024. The action followed Mylan’s ANDA filing and Paragraph IV notice challenging patents associated with nintedanib capsules marketed as Ofev. The docket is assigned to the Delaware federal patent docket and proceeds under the Hatch-Waxman framework.

Item	Detail
Court	U.S. District Court for the District of Delaware
Case number	1:24-cv-00082
Plaintiff	Boehringer Ingelheim Pharmaceuticals, Inc.
Defendant	Mylan Pharmaceuticals Inc.
Reference product	Ofev
Active ingredient	Nintedanib, generally administered as nintedanib esylate
Regulatory pathway	ANDA
Challenge type	Paragraph IV
Primary legal issue	Whether Mylan’s proposed product infringes enforceable Ofev patents
Regulatory consequence	Potential 30-month FDA approval stay under 21 U.S.C. § 355(j)(5)(B)(iii)

The complaint alleges patent infringement under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA containing a Paragraph IV certification as an act of infringement for purposes of determining whether the proposed generic product would infringe the listed patents.

What drug and dosage forms are protected in the case?

The litigation concerns nintedanib capsules. Ofev is supplied in 100-mg and 150-mg soft capsules. The standard adult dosage for idiopathic pulmonary fibrosis and other approved fibrosing lung indications is 150 mg twice daily, subject to dose reduction or interruption for adverse reactions, including gastrointestinal toxicity and liver-enzyme elevations. The 100-mg capsule provides a lower-dose option.

Nintedanib is a small-molecule tyrosine kinase inhibitor. Its pharmacology distinguishes it from biologic products and removes biosimilar regulation from the dispute. A competing manufacturer must satisfy the ANDA requirements for pharmaceutical equivalence, bioequivalence, chemistry, manufacturing and controls, labeling, and applicable patent certifications.

What formulations are protected by Ofev patents?

The Ofev patent estate can cover more than the active molecule. Relevant claim categories may include:

• Nintedanib or nintedanib salt compositions.
• Specific salt forms, including nintedanib esylate.
• Capsule formulations and excipient combinations.
• Pharmaceutical compositions with defined dissolution, stability, or release characteristics.
• Methods of treating idiopathic pulmonary fibrosis and related interstitial lung diseases.
• Dosing regimens involving dose reduction, treatment interruption, or administration for specified patient populations.
• Manufacturing processes and intermediates used to make the active pharmaceutical ingredient.

The practical strength of each patent depends on the claims asserted in the complaint, the ANDA formulation, the scope of Mylan’s Paragraph IV notice, and whether the claims survive claim construction, validity challenges, and infringement defenses.

What patents protect Ofev and nintedanib?

The Ofev patent portfolio includes compound, salt, formulation, method-of-use, and manufacturing-related rights. The patents listed for a reference product can change over time as patents issue, expire, are delisted, or are subject to FDA Orange Book corrections.

A public case analysis should distinguish between three patent groups:

Patent category	Commercial function	Typical generic defense
Compound patents	Protect nintedanib or a related chemical genus	Noninfringement, invalidity, expired claims
Salt and composition patents	Protect nintedanib esylate or a defined pharmaceutical composition	Different salt, formulation differences, invalidity
Method-of-use patents	Protect treatment of specified pulmonary diseases	Section viii carve-out, noninfringement, invalidity
Manufacturing patents	Protect production routes or intermediates	ANDA process does not practice the claimed method

The Orange Book is the controlling source for patents listed against the approved Ofev product. A patent may have commercial importance even when it does not block every generic presentation. For example, a method-of-use patent may be avoided through a labeling carve-out, while a composition patent can be more difficult to design around if the proposed product uses the same active ingredient and claimed salt.

When do Ofev patents expire?

Ofev exclusivity does not have one single expiration date. Patent expiration depends on the individual patent, terminal disclaimers, patent-term adjustment, patent-term extension, pediatric exclusivity, and any enforceable settlement or injunction.

FDA regulatory exclusivity for the original Ofev approvals expired well before the latest patent terms. Ofev received orphan-drug exclusivity for certain indications, but orphan exclusivity does not prevent an ANDA applicant from challenging patents or pursuing approval for an indication outside the protected orphan period.

The operative launch date therefore depends on the earliest date on which:

1. Mylan receives FDA approval;
2. The Hatch-Waxman litigation stay expires or is lifted;
3. The relevant asserted patent claims expire, are invalidated, or become unenforceable;
4. No settlement agreement imposes a later launch date; and
5. Mylan’s approved label and manufacturing process do not infringe surviving claims.

What was Mylan’s Paragraph IV challenge?

Mylan’s Paragraph IV certification represents its position that the relevant Ofev patents are invalid, unenforceable, or would not be infringed by the product described in its ANDA. Boehringer’s lawsuit is the statutory response that preserves its ability to seek patent remedies before FDA approval.

A Paragraph IV notice does not prove that the generic product will launch. It starts the patent dispute and can trigger the statutory 30-month stay if the brand plaintiff files suit within 45 days of receiving notice. The stay prevents FDA approval during the statutory period unless the court orders otherwise, the case is resolved, or the stay expires.

Mylan’s potential defenses include:

• The proposed nintedanib capsule does not meet one or more claim limitations.
• The asserted patent claims are anticipated or obvious.
• The claims lack written description or enablement.
• The asserted patent is unenforceable because of inequitable conduct.
• A method-of-use patent can be avoided through a section viii labeling carve-out.
• A manufacturing patent is not infringed because Mylan uses a different process.

What is the Orange Book status of Ofev?

Ofev is an FDA-approved small-molecule drug with Orange Book-listed patents. The Orange Book identifies patents that the NDA holder represents cover the drug, its approved uses, or approved drug products. It does not determine whether the patents are valid or infringed.

For the Mylan case, the Orange Book performs three commercial functions:

1. It identifies the patents challenged by Mylan’s ANDA certification.
2. It determines which patents can support a Hatch-Waxman infringement action.
3. It establishes the regulatory timing framework for FDA approval.

The Orange Book does not list every Boehringer patent. Unlisted patents can still be asserted in other contexts, but they generally do not create the same ANDA approval stay associated with an Orange Book-listed patent.

How strong is the Boehringer Ofev patent estate?

The estate has meaningful commercial value because nintedanib is a specialty product with limited therapeutic substitutes and technically specific formulation requirements. Its strength is strongest where claims cover the active ingredient, salt form, or formulation used by the ANDA. Method-of-use claims are more vulnerable to labeling strategies.

Risk factor	Assessment
Active ingredient dependence	High. A generic must use nintedanib to be therapeutically substitutable.
Salt and formulation exposure	Material. The exact API form and dosage form determine infringement risk.
Method-of-use vulnerability	Moderate to high where a section viii carve-out is available.
Manufacturing-patent exposure	Fact-specific and dependent on Mylan’s actual process.
Biosimilar risk	None. Nintedanib is a small molecule.
Substitution risk	High after approval because an AB-rated generic could receive pharmacy-level substitution, subject to state law.
Litigation leverage	Potentially significant if a composition or salt patent remains enforceable.

A patent estate is commercially strongest when it combines a product patent with formulation or use patents that are difficult to avoid. It is weaker when the remaining claims cover only narrow treatment methods or processes that an ANDA applicant can omit or design around.

What patent litigation affects Ofev generic entry?

The 1:24-cv-00082 case is one part of the broader Ofev generic-entry analysis. Other relevant proceedings may involve separate ANDA applicants, different Paragraph IV notices, different patents, or separate settlement terms. A judgment in one defendant’s case does not automatically resolve another applicant’s infringement dispute.

The most important litigation milestones are:

• Filing of the complaint.
• Answer and counterclaims.
• Claim-construction briefing and hearing.
• Fact and expert discovery.
• Summary-judgment motions.
• Trial or dispositive settlement.
• Final judgment and any appeal.
• FDA approval and the end of the statutory stay.

Public docket analysis should not treat the filing of the complaint as proof that the brand will prevail. The decisive record is the asserted claim set, the ANDA product description, the court’s claim construction, and the final judgment or settlement.

Are there licensing deals or settlement agreements?

A case-specific public settlement or license should be treated as controlling only if it appears in the docket, a court filing, an SEC disclosure, or a reliable settlement report. A private license, covenant not to sue, or agreed launch date can materially change the commercial forecast without changing the Orange Book expiration date.

The 1:24-cv-00082 docket should be reviewed for:

• Stipulations of dismissal.
• Consent judgments.
• Confidential settlement-related filings.
• Agreed protective orders.
• Joint status reports.
• Notices concerning FDA approval or launch rights.

Absent a publicly filed agreement, Mylan’s launch date cannot be inferred from the existence of the litigation alone.

What generic entry risks exist for Ofev?

Mylan has four principal entry scenarios.

Scenario 1: Early settlement launch

Boehringer and Mylan agree to a licensed entry date before all asserted patents expire. The settlement may include a royalty, supply arrangement, manufacturing restriction, or launch date tied to another patent event.

Scenario 2: Mylan wins on validity or infringement

A judgment that the asserted claims are invalid, unenforceable, or not infringed can remove the principal patent barrier. FDA approval would still depend on the ANDA review and the statutory stay.

Scenario 3: Boehringer prevails

A finding of infringement can produce an injunction or judgment barring commercial marketing until the relevant patent expires. The result may cover only certain strengths, formulations, indications, or manufacturing methods.

Scenario 4: Partial entry

Mylan obtains approval for a label that omits patented indications or launches a product that avoids specific formulation or method claims. This outcome can produce a narrower competitive effect than full AB-rated substitution.

How does Ofev patent risk compare with biosimilar risk?

Ofev presents generic, not biosimilar, risk. Mylan does not need to use the Public Health Service Act pathway or resolve patent disputes under the Biologics Price Competition and Innovation Act. The ANDA route generally offers a faster approval path after patent barriers are removed.

The principal difference is substitution. An approved therapeutically equivalent nintedanib generic may be eligible for pharmacy substitution, while biosimilar interchangeability involves separate FDA standards and state substitution rules. Ofev’s market exposure can therefore increase rapidly after the first AB-rated generic launch.

What are the revenue implications for Boehringer?

Ofev is a major specialty respiratory product, with global sales reported by Boehringer Ingelheim in its annual financial disclosures. U.S. revenue exposure depends on the timing of generic entry, the number of approved competitors, payer contracting, indication mix, and the extent to which generics receive substitution status.

The first generic entrant generally has greater pricing power than later entrants. Once multiple nintedanib suppliers enter, net prices can decline materially. Boehringer’s exposure is moderated by:

• Continued sales in non-U.S. markets with different patent and reimbursement timelines.
• Physician familiarity with Ofev.
• Patients requiring dose adjustments or specialized monitoring.
• Potential differences in generic availability by strength or indication.
• Contracting and distribution arrangements.

The most material valuation variable is not FDA approval alone. It is the first legally permitted commercial launch date for an AB-rated product and the number of competitors able to launch at that time.

Key Takeaways

• Case 1:24-cv-00082 is a Delaware Hatch-Waxman action involving Mylan’s proposed generic nintedanib product for Ofev.
• Mylan filed a Paragraph IV challenge, and Boehringer responded with an ANDA infringement complaint.
• Ofev is a small-molecule product. Biosimilar rules do not apply.
• The Orange Book patents, not FDA regulatory exclusivity alone, determine the principal generic-entry barrier.
• Product, salt, formulation, method-of-use, and manufacturing claims carry different levels of generic-entry risk.
• A section viii carve-out may reduce the effect of method-of-use patents.
• The commercial forecast depends on the final asserted claims, the outcome or settlement of the case, FDA approval, and any agreed launch restrictions.
• Ofev faces potentially rapid price erosion after the first approved and substitutable nintedanib generic.

FAQs About Boehringer Ingelheim v. Mylan and Ofev

Is Ofev a biologic drug?

No. Ofev contains nintedanib, a small-molecule tyrosine kinase inhibitor. Generic applicants use the ANDA pathway rather than the biosimilar pathway.

Can Mylan launch before every Ofev patent expires?

Potentially. Mylan may launch before all patents expire if it prevails, obtains a covenant or license, uses a noninfringing product, receives approval with a permissible labeling carve-out, or reaches a settlement with an authorized entry date.

Does a Paragraph IV certification mean FDA approved Mylan’s generic?

No. Paragraph IV is a patent certification made during the ANDA process. It does not establish FDA approval, therapeutic equivalence, or a legal right to market.

Can Ofev method-of-use patents block all generic indications?

Not necessarily. A generic applicant may omit patented indications through a section viii statement if the resulting label and marketing conduct avoid infringement. Product and formulation patents can create broader barriers.

What event would most directly increase Ofev generic-entry risk?

The most direct trigger is a final judgment eliminating the asserted patent barrier or a settlement granting Mylan a defined launch license, followed by FDA approval of an ANDA eligible for therapeutic substitution.

References

1. U.S. District Court for the District of Delaware. (2024). Boehringer Ingelheim Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 1:24-cv-00082. PACER docket.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Ofev prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.

4. U.S. Code, 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.

5. U.S. Code, 35 U.S.C. § 271(e)(2). Infringement relating to regulatory submissions.